French biotech raises $75M for new cell therapy manufacturing tech, Parkinson's treatment

A French cell therapy startup is getting two new offices in opposite parts of the world, and a new CEO to boot as it announces a new round of funding Monday.

Biotech TreeFrog Therapeutics, which is focused on stem cell therapy, closed a $75 million Series B, the company announced. The round brings the company’s total funding to $83 million, and allows them to open up offices in Boston and Kobe, Japan, as it advances its biomimetic C-Stem technology for clinical manufacturing.